Purdue Pharma Signs Exclusive License Agreement with Klaria for its KL-01401

 Purdue Pharma Signs Exclusive License Agreement with Klaria for its KL-01401

Purdue Pharma Signs Exclusive License Agreement with Klaria for its KL-01401

Shots:

  • Klaria to receive $55.2M as total deal value, including $5.2M as near-term milestones and royalties on sales from Purdue. Purdue to get exclusive license rights to develop & commercialize Klaria’s KL-01401
  • Klaria will take care the manufacture and supply of KL-01401 developed using its own drug delivery technology and has granted it patent rights to Uppsalagruppen Medical. Uppsalagruppen to receive 4% royalties on sales of KL-01401 from Klaria
  • KL-01401 is an adrenaline formulation indicated to treat the increased risk of anaphylactic shock in patients with anaphylactic reactions

Click here to read full press release/ article | Ref: Klaria | Image: Alamy

 

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post